The exchangeable notes are due 2030

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by Jazz Investments I Limited, a wholly owned subsidiary of Jazz Pharmaceuticals plc, of $1 billion aggregate principal amount of its 3.125% exchangeable senior notes due 2030, which included $150 million aggregate principal amount of notes issued pursuant to the exercise in full of the initial purchasers’ option to purchase additional notes. The notes are fully and unconditionally guaranteed by Jazz Pharmaceuticals.

Headquartered in Dublin, Ireland, Jazz Pharmaceuticals is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Jonathan Bye, Paula Gergen, Sunny Xu, Dove Barbanel and Ivey Eugene. Partner Aliza Slansky and associate Eytan de Gunzburg provided tax advice. Partner David R. Bauer and associate Joshua Shirley provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post